DERM News and Press, Journey Medical Corporation From 10/08/25

SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA...

2025-09-06 08:44:27 ET Once a quarter, I like to go back through some of my previous investments and trades to review my execution, analysis, and also just reference what was happening in the healthcare sector at that time. Well, I was going back pre-pandemic and found several tickers I...

SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA&#x...

2025-08-14 16:15:00 ET Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry's major underlying drivers — higher rates of cancer and chronic disease ...

2025-08-12 18:43:21 ET More on Journey Medical Journey Medical Corporation (DERM) Q2 2025 Earnings Call Transcript Journey Medical Corporation (DERM) Q1 2025 Earnings Call Transcript Journey Medical GAAP EPS of -$0.18 beats by $0.06, revenue of $13.1M beats by $1.05M...

2025-08-12 18:42:42 ET Journey Medical Corporation (DERM) Q2 2025 Earnings Conference Call August 12, 2025 04:30 PM ET Company Participants Claude Maraoui - Founder, President, CEO & Director Jaclyn Jaffe - Senior Director of Corporate Operations Joseph M. Be...

2025-08-12 17:33:38 ET More on Journey Medical Journey Medical Corporation (DERM) Q1 2025 Earnings Call Transcript Journey Medical GAAP EPS of -$0.18 beats by $0.06, revenue of $13.1M beats by $1.05M Journey Medical outlines Emrosi launch momentum and targets expande...

2025-08-12 16:58:14 ET More on Journey Medical Journey Medical GAAP EPS of -$0.18 beats by $0.06, revenue of $13.1M beats by $1.05M Journey Medical outlines Emrosi launch momentum and targets expanded payer access in 2025 Seeking Alpha’s Quant Rating on Journe...

S econd quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today...

Reeds Inc. (REED) is expected to report $-0.04 for Q2 2025 Jerash Holdings (US) Inc. (JRSH) is expected to report for Q1 2026 Churchill Capital Corp IX (CCIX) is expected to report for quarter end 2025-06-30 Verde Clean Fuels Inc. (VGAS) is expected to report for Q2 2025 Mobile In...